EXPERIENCE OF INTRAMUSCULAR METHOTREXATE USE IN A PATIENT WITH EARLY POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

This article presents a case of severe course of polyarticular juvenile idiopathic arthritis. Active articular syndrome, high laboratory parameters of disease activity, severe incompetence were observed in a child by the therapy initiation. Successful use of intramuscular methotrexate in the dose of 15 mg/m² of body surface per week is described. Exudative articular alterations, arthralgiae, morning stiffness duration reduced as early as one month after the therapy initiation in a child. Acute inflammatory articular alterations cut off, range of motions recovered completely in 4 out of the 6 affected joints, laboratory parameters of disease activity reduced and normalized (ESR and CRP), inactive disease stage was registered after 6 months of treatment. We did not observe any undesirable phenomena in the setting of methotrexate therapy.

1. Cassidy R. Petty (eds.). Texbook of paediatric rheumatology. 6th Ed. J. Philadelphia: Saunders Elsevier. 2011.

2. Atlas redkikh boleznei. Pod red. A.A. Baranova, L.S. Namazovoi-Baranovoi [Atlas of Rare Diseases. Edited by A.A. Baranov, L.S. Namazova-Baranova]. Moscow, Pediatr, 2013. 304 p.

3. Ringold S., Weiss F. P., Beukelman T., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Nigrovic P. A., Robinson A. B., Vehe R. K. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Arthritis & Rheumatism. 2013; 65 (10): 2499–2512.

4. Beukelman T., Nivedita M. Patkar, Kenneth G. Saag, Tolleson-Rinehart S., Randy Q. Cron, Esi M. Dewitt, Norman T. Ilowite, Kimura Y., Ronald M. Laxer, Daniel J. Lovell, Martini A., Rabino vich C. E., Ruperto N. American College of Rheumatology Recom mendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care & Research. 2011; 63(4): 465–482.

5. Baranov A.A., Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Karagulyan N.A., Litvitskii P.F., Mitenko E.V., Sleptsova T.V., Fetisova A.N., Chistyakova E.G., Taibulatov N.I., Morev S.Yu. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12(1): 37–56.

6. Alexeeva E.I., Sleptsova T.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Mitenko E.V., Chistyakova E.G., Fetisova A.N., Taibulatov N.I. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12(4): 38–46.

7. Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res. (Hoboken). 2012 Sep; 64 (9): 1349–56.

8. Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis. Arch. Dis. Child. 2003; 88: 197–200.

9. Alexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit. Etiologiya, patogenez. Klinika. Algoritmy diagnostiki i lecheniya [Juvenile Rheumatoid Arthritis. Etiology, Pathogenesis. Clinical Pattern. Diagnosis and Treatment Algorithms]. Moscow, Vedi, 2007. 359 p.

10. Bzarova T. M., Alexeeva E.I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.

11. Denisova R.V., Alexeeva E.I., Al'bitskii V.Yu., Vinyarskaya I.V., Valieva S.I. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8(3): 18–26.

12. Baranov A.A., Nasonov E.L., Alekseeva E.I., Erdes Sh.F., Il'in A.G. Voprosy sovremennoi pediatrii = Current pediatrics. 2007; 6(1): 6–8.

13. Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow–up from disease onset. Ann. Rheum. Dis. 2000; 59: 954–958.

14. Nasonov E.L. Protivovospalitel'naya terapiya revmaticheskikh boleznei [Anti-inflammatory Therapy of Rheumatic Diseases]. Moscow, M-Siti, 1996. 345 p.

15. Alarcon G. S. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In Arthritis and Allied Conditions. A Text book of rheumatology, 13th Edition; еd. W. J. Koopman. Baltimore, Philadelphia, London: Williams & Wilkins. 1997; 1: 679–698.

16. Cronstein B. N. The mechanism of action of methotrexate. Rheum. Dis. Clin. North Amer. 1997; 23: 739–755.

17. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.

18. Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J. Pediatr. 1998; 133: 179–180.

19. Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999; 81: 766–772.

20. Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N. Engl. J. Med. 1992; 326: 1043–1049.

21. Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr Rheum. 2000; 43 (8): 1849–1857.

22. Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352: 1655–1666.

23. Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2009; 27 (6): 1047–1053.

24. Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191–2201.

25. Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.

26. J. Rheumatol. 2004; 31 (1): 179–182.

27. Kugathasan S., Newman A. J., Dahms B. B. et al. Liver biopsy findings liver in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J. Pediatr. 1996; 128 (1): 149–151.

28. Cron R. Q., Sherry D. D., Wallace C. A. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J. Pediatr. 1998; 132 (5): 901–902.

29. Masaaki Mori, Takuya Naruto, Tomoyuki Imagawa, Takuji Murata, Syuji Takei, Minako Tomiita, Yasuhiko Itoh, Satoshi Fujikawa, Shumpei Yokota. Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod. Rheumatol.Feb; 19 (1): 1–11.

30. Beukelman T., Haynes K., Curtis J. R., Xie F., Chen L., Bemrich- Stolz C. J., Delzell E., Saag K. G., Solomon D. H., Lewis J. D. On behalf of the Safety Assessment of Biological therapeutics (SABER) Collaboration. Rates of Malignancy Associated with Juvenile Idiopathic Arthritis and Its Treatment. Arthritis Rheum. 2012 April; 64 (4): 1263–1271.

31. Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 2011 Sep; 70: 1605–1612.

32. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert. Opin. Biol. Ther. 2013 Mar; 13 (3): 361–76.

33. Otten M. H., Anink J., Spronk S., van Suijlekom-Smit L. W. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann. Rheum Dis. 2013 Nov 1; 72(11): 1806–1812.

34. Alexeeva E.I., Sleptsova T.V., Valieva S.I., Bzarova T.M., Denisova R.V., Lisitsyn A.O., Gudkova E.Yu., Chomakhidze A.M., Isaeva K.B., Grigor'eva A.A., Lomakina O.L. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8(4): 42–50.

35. Lovell D. J., Ruperto N., Goodman S. Reiff A., Jung L Jarosova K. et al. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359: 810–820.

36. Frampton J. E. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Paediatr. Drugs. 2013 Dec; 15(6): 515–31.